Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of L-Adrenaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racepinephrine SCHEMBL29396039 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL3815 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Epinephrine SCHEMBL29353423 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| [11C]Epinephrine SCHEMBL29374823 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Epinephrine SCHEMBL2837188 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| [11C]Epinephrine SCHEMBL29371663 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| L-Adrenaline SCHEMBL29519331 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL11631789 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL20493843 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Epinephrine SCHEMBL8576894 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 219367 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034074-A1 | EPINEPHRINE FORMULATIONS | PAR PHARMACEUTICAL INC (US) | 2026-02-05 | — | — | US | claimed |
| US-12310930-B2 | Stabilization of epinephrine formulations | YS PHARMTECH (US) | 2025-05-27 | — | — | US | claimed |
| US-20250152524-A1 | TOPICAL COMPOSITIONS AND METHODS | VASODYNAMICS LIMITED (GB) | 2025-05-15 | — | — | US | claimed |
| US-12290493-B2 | More potent and less toxic formulations of epinephrine and methods of medical use | ADVANCED RESPIRATORY TECHNOLOGIES, INC. (US) | 2025-05-06 | — | — | US | claimed |
| CN-119757509-A | Application of cyclodextrin in analysis of catecholamine molecular isomers and analysis method | 常州华班亚生物科技有限公司 | 2025-04-04 | — | — | CN | claimed |
| EP-4486299-A1 | TOPICAL COMPOSITIONS AND METHODS | Vasodynamics Limited (GB) | 2025-01-08 | — | — | EP | claimed |
| CN-119212680-A | Topical compositions and methods | 瓦索达纳米有限公司 | 2024-12-27 | — | — | CN | claimed |
| WO-2024151515-A2 | ANTI-TNFR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | claimed |
| WO-2024152001-A1 | CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR THE TREATMENT AND PREVENTION OF SJÖGREN'S SYNDROME | VIELA BIO, INC. (US) | 2024-07-18 | — | — | WO | claimed |
| US-20240238257-A1 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | SANOFI (FR) | 2024-07-18 | — | — | US | claimed |
| US-4393050-A | ANTISECRETORY AGENTS, HORMONE INHIBITORS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1983-07-12 | — | — | US | claimed |
| US-4388236-A | OPIATE AGONISTS, ANALGESICS | HOFFMANN-LA ROCHE INC. (US) | 1983-06-14 | — | — | US | claimed |
| US-4339442-A | Gynosaponins, their use and a process for preparing the same | TAKEMOTO TSUNEMATSU | 1982-07-13 | — | — | US | claimed |
| US-4317816-A | TREATMENT WITH GLUCOCORTICOID AND SAPOININ OF GINSENG | OSAKA CHEMICAL LABORATORY CO., LTD. (JP) | 1982-03-02 | — | — | US | claimed |
| US-4258049-A | Inhibiting phenylethanolamine N-methyltransferase with thiadiazolo and oxadiazolotetrahydroisoquinolines | SMITHKLINE CORPORATION (US) | 1981-03-24 | — | — | US | claimed |
| US-4230684-A | RADIOIMMUNOASSAY | CORNELL RESEARCH FOUNDATION, INC. (US) | 1980-10-28 | — | — | US | claimed |
| US-4167562-A | Method and composition for treating arteriosclerosis | EVERS H RAY | 1979-09-11 | — | — | US | claimed |
| US-4075334-A | ADRENAL GLANDS | MALLINCKRODT, INC. (US) | 1978-02-21 | — | — | US | claimed |
| US-4017361-A | Process for obtaining continuous lines of tumoral cells in vitro | CHOAY S.A. (FR) | 1977-04-12 | — | — | US | claimed |
| US-3944671-A | ALPHA-(4-AMINOPHENYL)-ALPHA-LOWER ALKYL GLUTARIMIDES OR SALTS | CIBA-GEIGY CORPORATION (US) | 1976-03-16 | — | — | US | claimed |